Exhalation Delivery System With Fluticasone Effective for Rhinosinusitis
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 26, 2024 -- For patients with chronic rhinosinusitis (CRS), an exhalation delivery system that delivers fluticasone (EDS-FLU) to sinonasal areas above the inferior turbinate is efficacious, irrespective of nasal polyps, according to a study published online Jan. 18 in the Journal of Allergy and Clinical Immunology: In Practice.
James N. Palmer, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined EDS-FLU efficacy for CRS in two randomized, EDS-placebo-controlled trials in adults with CRS irrespective of polyps (ReOpen1; 332 patients) or exclusively without polyps (ReOpen2; 223 patients). For 24 weeks, patients received EDS-FLU one or two sprays/nostril or EDS-placebo twice daily.
The researchers found that the composite symptom score least-squares mean change for EDS-FLU one or two sprays/nostril versus EDS-placebo was −1.58 and −1.60 versus −0.62 in ReOpen1, and −1.54 and −1.74 versus −0.81 in ReOpen2. Sinus opacification least-squares mean change for one or two sprays/nostril of EDS-FLU versus EDS-placebo was −5.58 and −6.20 versus −1.60 in ReOpen1 and −7.00 and −5.14 versus +1.19 in ReOpen2. Compared with EDS-placebo, acute disease exacerbations were reduced by 56 to 66 percent with EDS-FLU. For patients using standard-delivery nasal steroid products just before entering the study, there were significant symptom reductions of a similar magnitude observed. Similar adverse events were seen to those with standard-delivery intranasal steroids.
"These findings provide strong evidence for an effective, noninvasive treatment option for people who continue to experience symptoms after over-the-counter medications have failed," Palmer said in a statement.
Several authors disclosed ties to pharmaceutical companies, including OptiNose US, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Clinical Signs Tied to Rhinosinusitis ID'd in Patients With Nasal Allergies
MONDAY, March 11, 2024 -- Clinical signs associated with chronic rhinosinusitis (CRS) have been identified for patients presenting with a chief complaint of nasal allergies...
Sinusitis Linked to Increased Risk for Subsequent Rheumatic Disease
WEDNESDAY, Feb. 28, 2024 -- A history of sinusitis is associated with an increased incidence of rheumatic disease, according to a study published online Feb. 27 in RMD...
ChatGPT Provides High-Quality Responses to Nose Job Surgical Questions
FRIDAY, Dec. 29, 2023 -- ChatGPT delivers accurate, complete, and high-quality responses to preoperative and postoperative patient questions related to septorhinoplasty, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.